Elicio Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Elicio Therapeutics, Inc. (ELTX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 6.93 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- Elicio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 6.91M shares, a 17.03% increase year-over-year.
- Elicio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 5.91M shares, a 215.96% increase year-over-year.
- Elicio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 1.87M shares, a 68.85% decline year-over-year.
- Elicio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 6.00M shares, a 16.25% decline year-over-year.
- Elicio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 6.18M shares, a 42.33% increase from fiscal 2024.
- Elicio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 4.34M shares, a 197.93% increase from fiscal 2023.
- Elicio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 1.46M shares, a 75.74% decline from fiscal 2022.
- Elicio Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 6.00M shares, a 7.57% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 6.93M shares 10-Q · filed 2026-08-13 | |||||||
| 2026-03-31 | 6.91M shares 10-Q · filed 2026-05-11 | |||||||
| 2025-12-31 | 6.18M shares 10-K · filed 2026-03-12 | |||||||
| 2025-09-30 | 6.02M shares 10-Q · filed 2025-11-13 | |||||||
| 2025-06-30 | 6.27M shares 10-Q · filed 2026-08-13 | |||||||
| 2025-03-31 | 5.91M shares 10-Q · filed 2026-05-11 | |||||||
| 2024-12-31 | 4.34M shares 10-K · filed 2026-03-12 | |||||||
| 2024-09-30 | 3.27M shares 10-Q · filed 2025-11-13 | |||||||
| 2024-06-30 | 904.30K shares 10-Q · filed 2025-08-07 | |||||||
| 2024-03-31 | 1.87M shares 10-Q · filed 2025-05-13 | 1.87M shares 10-Q · filed 2024-05-15 | ||||||
| 2023-12-31 | 1.46M shares 10-K · filed 2025-03-31 | |||||||
| 2023-09-30 | 1.46M shares 10-Q · filed 2024-11-13 | |||||||
| 2023-06-30 | 1.43M shares 10-Q · filed 2024-08-13 | |||||||
| 2023-03-31 | 6.00M shares 10-Q · filed 2024-05-15 | 4.84M shares 10-Q · filed 2023-05-10 | ||||||
| 2022-12-31 | 6.00M shares 10-K · filed 2024-03-29 | 4.89M shares 10-K · filed 2023-03-17 | ||||||
| 2022-09-30 | 2.56M shares 10-Q · filed 2023-11-13 | 6.74M shares 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | 2.45M shares 10-Q · filed 2023-08-14 | 7.11M shares 10-Q · filed 2022-08-15 | ||||||
| 2022-03-31 | 7.17M shares 10-Q · filed 2023-05-10 | |||||||
| 2021-12-31 | 5.58M shares 10-K · filed 2023-03-17 | |||||||
| 2021-09-30 | 5.59M shares 10-Q · filed 2022-11-14 | |||||||
| 2021-06-30 | 5.69M shares 10-Q · filed 2022-08-15 | |||||||
| 2021-03-31 | 5.65M shares 10-Q · filed 2022-05-16 | |||||||
| 2020-12-31 | 15.82M shares 10-K · filed 2022-03-30 | |||||||
| 2020-09-30 | 16.35M shares 10-Q · filed 2021-11-12 | |||||||
| 2020-06-30 | 7.24M shares 10-Q · filed 2021-08-12 | |||||||
| 2020-03-31 | 6.33M shares 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |